Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2025)

Historic FCF Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 19170.41%.

  • BioXcel Therapeutics' FCF Margin fell 115358300.0% to 19170.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 7741.22%, marking a year-over-year decrease of 40469800.0%. This contributed to the annual value of 3178.6% for FY2024, which is 80551700.0% up from last year.
  • BioXcel Therapeutics' FCF Margin amounted to 19170.41% in Q3 2025, which was down 115358300.0% from 10479.17% recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' FCF Margin peaked at 464757.14% during Q1 2022, and registered a low of 25414.08% during Q1 2023.
  • Moreover, its 4-year median value for FCF Margin was 7634.58% (2024), whereas its average is 21484.44%.
  • As far as peak fluctuations go, BioXcel Therapeutics' FCF Margin plummeted by 2000000000bps in 2023, and later skyrocketed by 223718100bps in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' FCF Margin stood at 16234.87% in 2022, then soared by 56bps to 7144.41% in 2023, then surged by 43bps to 4046.17% in 2024, then crashed by -374bps to 19170.41% in 2025.
  • Its FCF Margin stands at 19170.41% for Q3 2025, versus 10479.17% for Q2 2025 and 7168.45% for Q1 2025.